Managing Toxicity of Intravesical Therapy

Abstract Intravesical therapies have shown positive effects both on recurrence and progression of non–muscle-invasive bladder cancer. However, more than 50% of patients experience untoward side effects associated with treatment. In order to reduce the rate of patients who discontinue treatment due to side effects, prevention and effective management of treatment-related toxicity is essential.